Upcoming Events
  1. ALTG closed SAC and MAC meetings

    May 1 @ 8:00 am - 5:00 pm
  2. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 10:00 am - October 24 @ 3:30 pm
  3. ALTG open MAC and SAC meetings

    November 20

ALTG Clinical trials

ALTG Clinical trials

We’re excited to announce that DREAM3R, an international multi-centre Phase III trial evaluating upfront immunotherapy (durvalumab) in mesothelioma, is in the startup phase, with the lead ethics submission planned for November. Expression Of Interests (EOIs) for site participation are expected to be sent to all ALTG members in December from the altg@lungfoundation.com.au email.

Diagram: DREAM3R

BR.31, a Phase III Prospective Double-Blind Placebo Controlled Randomised Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer (NSCLC) surpassed local recruitment expectations before closing on 19 October. An interim analysis is planned for late 2020.

A final analysis of BR.34, a randomised trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk advanced or metastatic (stage IIIB/IV) squamous or non-squamous NSCLC, is scheduled for early 2020.

Nine concepts were presented at the Scientific Advisory Committee (SAC) meeting on 8 November. We are now calling for trial concepts and ideas to be discussed at the February ALTG meetings to be submitted by 19 January to altg@lungfoundation.com.au We encourage submissions from all members’ disciplines and special interest areas.

More details on the review process can be found here, including a links to the trial concept and guide for submission.

More details on the ALTG clinical trials programme can be found here.